MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 13.3% from a year ago
Property, plant & equipment (net) stood at $6.23M at the end of Q1 FY2026, down 13.3% from a year earlier and down 5.4% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Property, plant & equipment (net) amounted to 1.5% of total assets at the end of Q1 FY2026, down 5.0 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -13.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 6.58M USD
- Year-over-year change
- -12.9%
- 3-year CAGR
- -2.6%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.58M | -12.9% |
| FY2024 | 2024-12-31 | 7.56M | +14.8% |
| FY2023 | 2023-12-31 | 6.59M | -7.6% |
| FY2022 | 2022-12-31 | 7.12M | — |
Property, Plant & Equipment (Net) vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 property, plant & equipment (net) of $6.23M is the 4th highest of the 11 companies compared; the peer median is $1.05M.
- Its year-over-year change of -13.3% is the 4th highest of 9, against a peer median of -15.9%.
- Property, plant & equipment (net) amounts to 1.5% of total assets for MPLT, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $11.85M | +8.9% | +237.6% | 2.4% |
| Mar 2026 | $11.52M | -10.4% | — | 5.1% | |
| Mar 2026 | $6.3M | -14.0% | +57.2% | 2.3% | |
| Mar 2026 | $6.23M | -13.3% | -2.6% | 1.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.63M | -8.3% | +975.5% | 0.9% |
| Mar 2026 | $1.52M | -26.3% | -1.5% | 0.5% | |
| Mar 2026 | $580K | -17.7% | +85.6% | 0.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $390K | -79.3% | -65.0% | 0.3% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $1.05M | -15.9% | +71.4% | 0.4% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.